What is CJC-1295 + Ipamorelin?
The blend contains 5mg CJC-1295 without DAC and 5mg ipamorelin, combining two distinct routes into pituitary growth-hormone signalling. The GHRH analogue acts through the GHRH receptor; ipamorelin is a pentapeptide associated with the ghrelin receptor, GHS-R1a. The paired format is relevant to experiments that compare converging endocrine inputs.
A combined receptor rationale is different from demonstrating a superior response from this finished formulation. Equal component masses also give unequal molar amounts, and a prepared blend cannot independently vary either input. Interpretation therefore depends on comparison with the individual compounds and appropriate mixture controls. The CJC component retains the same identity boundary as the single no-DAC product: 29 residues and D-Ala2 are documented, while a complete four-substitution sequence is not established by the available Lynx record.
CJC-1295 + Ipamorelin Research Areas
D-amino-acid substitution at position 1 or 2 protected defined GHRH preparations against cleavage by DPP-IV in plasma experiments. Native and shortened GHRH fragments were readily cleaved near the N-terminus, with additional trypsin-like degradation contributing less. This explains the interest in position-2 modifications without establishing the rest of a catalogue analogue’s sequence.
Frohman et al. · J Clin Invest · 1989PubMed
Ipamorelin stimulated growth-hormone release in rat pituitary cells and animal experiments. In swine comparisons, GHRP-2 and GHRP-6 raised ACTH and cortisol, while ipamorelin did not produce significant increases above the GHRH comparison. This is the basis for its relative selectivity under those conditions, rather than a guarantee of an identical hormonal profile in every model.
Raun et al. · Eur J Endocrinol · 1998PubMed
Molecular profile
CJC-1295 (no DAC)
- Amount
- 5 mg
- Sequence
- Tyr-D-Ala-
Asp-Ala- Ile-Phe- Thr-Gln- Ser-Tyr- Arg-Lys- Val-Leu- Ala-Gln- Leu-Ser- Ala-Arg- Lys-Leu- Leu-Gln- Asp-Ile- Leu-Ser-Arg-NH₂ - Residue count
- 29
- Molecular formula
- C152H252N44O42
- Molecular weight
- 3358.0 g/mol
- Chemical class
- Synthetic GHRH analogue without DAC
Ipamorelin
- Amount
- 5 mg
- Sequence
- Aib-His-
D-2-Nal-D-Phe-Lys-NH2 - Residue count
- 5
- Molecular formula
- C38H49N9O5
- Molecular weight
- 711.9 g/mol
- CAS number
- 170851-70-4
- Chemical class
- Synthetic ghrelin-receptor agonist pentapeptide
Analytical verification
This report identifies the blend, but does not state component quantities. The listed vial composition is the catalogue specification, not a quantity result from this certificate.
- Lynx report reference
- UKLY-961
- Reported purity
- >99%
- Analysis method
- RP-HPLC (UV 214 nm)
- Identity result
- CJC-1295 (no DAC): Confirmed; Ipamorelin: Confirmed
- Analysis date
- 7 Aug 2026
- Report date
- 7 Aug 2026
- Laboratory
- Marfleet Analytical Services Ltd
Storage & Reconstitution
Store in appropriate cool, dry conditions. Refer to product-specific storage information when published.
Vials are supplied separately from bacteriostatic water and other preparation supplies.
For laboratory handling context, read Research peptide storage and stability. Product-specific information and the laboratory method take precedence.
For laboratory preparation, allow the sealed vial to reach room temperature before opening. Wipe the vial stopper and bacteriostatic-water stopper with an alcohol wipe. Add bacteriostatic water slowly down the inside wall of the vial, then swirl gently until dissolved. Do not shake.
Research literature
- Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.Henninge et al. · Drug Test Anal · 2010PubMed
- Ipamorelin, the first selective growth hormone secretagogue.Raun et al. · Eur J Endocrinol · 1998PubMed
- Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma.Frohman et al. · J Clin Invest · 1989PubMed
CJC-1295 + Ipamorelin Price (UK)
CJC-1295 + Ipamorelin is a 5 mg + 5 mg research blend containing CJC-1295 5 mg and Ipamorelin 5 mg. The current price is £39.99.
Current availability is shown below. UK orders of £49.99 or more qualify for free standard shipping. Eligible working-day orders placed before 4 PM are dispatched the same day.
| Vial size | Current price | Price / mg | Status |
|---|---|---|---|
| 5 mg + 5 mg | £39.99 | £4.00/mg | Checking stock |
Common questions about CJC-1295 + Ipamorelin
What is CJC-1295 + Ipamorelin?
It is a lyophilised research blend of CJC-1295 without DAC and Ipamorelin. CJC-1295 is associated with the GHRH pathway, while Ipamorelin acts through the ghrelin receptor. Bringing them into one vial allows two different inputs into growth-hormone signalling to be studied in the same preparation, rather than treating them as the same peptide.
What is in the 5+5MG CJC-1295 + Ipamorelin vial?
The formulation lists 5mg CJC-1295 without DAC and 5mg Ipamorelin in one vial. The badge shows the amount of each component, not 10mg of either peptide. Certificate UKLY-961 identifies both peptides and reports blend purity, but does not state their quantities, so the formulation amounts and the laboratory findings answer different questions.
Why are CJC-1295 and Ipamorelin studied together?
They act through different signalling pathways linked to growth-hormone research. CJC-1295 targets the GHRH pathway, while Ipamorelin acts at the ghrelin receptor. Studying them together lets a laboratory compare a two-pathway preparation with individual compounds, helping separate the response to each input from the response observed when both are present.
How does CJC-1295 differ from Ipamorelin?
The CJC component is a 29-amino-acid GHRH analogue; Ipamorelin is a five-amino-acid peptide acting through the ghrelin receptor. Their different receptor targets are more useful to understand than their size alone. Both can be studied using growth-hormone-related measurements, but the signal starts at a different receptor in each case.
Does this blend contain CJC-1295 with DAC?
No. The formulation uses CJC-1295 without DAC. The with-DAC version has an albumin-binding modification that changes its persistence in circulation, and is a separate product. This blend combines the without-DAC CJC component with Ipamorelin; adding a second peptide does not add the DAC feature or reproduce the with-DAC molecular design.
How does the blend differ from the individual compounds?
The blend keeps CJC-1295 and Ipamorelin at a fixed mass ratio, so both change together when the preparation is diluted. Individual vials let a laboratory vary one while holding the other constant, or test each alone. Those comparisons help identify whether a measured response comes from one pathway or the combined preparation.
What does lyophilised mean for this blend?
It means the combined formulation is supplied as a freeze-dried powder, not a ready-made liquid. Bringing it into solution changes its concentration but does not separate CJC-1295 from Ipamorelin. The two components remain in the listed mass ratio, which matters when a laboratory plans comparisons with individual compounds or prepares controls.
Can I buy CJC-1295 + Ipamorelin in the UK for research?
Yes. Lynx supplies this CJC-1295 without DAC and Ipamorelin blend in the UK for in-vitro laboratory research. Check the 5+5MG vial option for current availability.
Is the CJC-1295 + Ipamorelin blend independently batch tested?
Marfleet Analytical Services Ltd tested the blend by RP-HPLC (UV 214 nm). Certificate UKLY-961 reports purity above 99%; it does not give the quantities of the two components.
